NICE (UK) terminated appraisal for Ofev (nintedanib) for treating fibrosing interstitial lung disease in people 6 to 17 years – Boehringer Ingelheim

NICE(UK): NICE is unable to make a recommendation about the use in the NHS of nintedanib for treating fibrosing interstitial lung disease in people 6 to 17 years.

This is because Boehringer Ingelheim did not provide an evidence submission. The company has confirmed that it does not intend to make a submission for the appraisal.

The company considers that there is insufficient new evidence to provide a submission for this appraisal at this time.